Form 4: Serina Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Richard Peter Marshall acquired 40,000 stock options in Serina Therapeutics on April 1, 2024.
Summary
- Richard Peter Marshall, a director of Serina Therapeutics, acquired 40,000 stock options on April 1, 2024.
- The exercise price of the options is $11.828.
- The options expire on April 1, 2034.
- The options vest in three equal installments on April 1, 2025, April 1, 2026, and April 1, 2027, contingent upon continued service to the issuer.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition by a director.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of stock option acquisition and first vesting date. |
| 04/01/2025 | First vesting date of the stock options. |
| 04/01/2026 | Second vesting date of the stock options. |
| 04/01/2027 | Third vesting date of the stock options. |
| 04/01/2034 | Expiration date of the stock options. |
| 04/03/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.